Neurotoxic Effects of Childhood Cancer Therapy and Its Potential Neurocognitive Impact

Article Tools REVIEW ARTICLES Neurocognitive Outcomes in Survivors of Pediatric Cancer Article Tools OPTIONS Elizabeth S. Duke, MD2xElizabeth S. DukeSearch for articles by this author; Hannah-Lise T. Schofield, PhD3,4xHannah-Lise T. SchofieldSearch for articles by this author; and Nicole J. Ullrich, MD, PhD5xNicole J. UllrichSearch for articles by this author Show More 1Department of Epidemiology and Cancer Control, St. Jude Children's Research Hospital, Memphis, TN2Center for Cancer and Blood Disorders, Children's National Hospital, Washington, DC3Department of Child and Adolescent Psychiatry and Behavioral Sciences, Children's Hospital of Philadelphia, Philadelphia, PA4Perelman School of Medicine of the University of Pennsylvania, Philadelphia, PA5Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Harvard Medical School, Boston, MA https://doi.org/10.1200/JCO.20.02533 First Page Full Text PDF Figures and Tables © 2021 by American Society of Clinical OncologyCONTEXTKey ObjectiveHow do the neurotoxic effects of traditional and emerging chemotherapies potentially affect neurocognitive outcomes?Knowledge GeneratedThere is growing body of evidence that traditional treatments and emerging therapies influence the development of cancer-related neurocognitive impairments, which can progress over time. More long-term data are needed to better characterize chronic neurologic deficits and neurocognitive outcomes related to use of all modalities of treatment for childhood cancer, and in particular emerging immunotherapy and molecularly targeted therapies.RelevanceThis article provides an overview of the factors that contribute to impaired neurocognitive function in childhood cancer survivors and provides a framework for consideration of potential areas for primary prevention by reducing treatment-related toxicity, as well as informing potential interventions.SUPPORTSupported in part by research funding from the National Cancer Institute (T32 CA225590, N.S.P. appointee).AUTHOR CONTRIBUTIONSConception and design: All authorsCollection and assembly of data: Nicholas S. Phillips, Nicole J. UllrichData analysis and interpretation: Nicholas S. Phillips, Nicole J. UllrichManuscript writing: All authorsFinal approval of manuscript: All authorsAccountable for all aspects of the work: All authorsAUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTERESTNeurotoxic Effects of Childhood Cancer Therapy and Its Potential Neurocognitive ImpactThe following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/jco/authors/author-center.Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments).Nicole J. UllrichHonoraria: AstraZenecaPatents, Royalties, Other Intellectual Property: UpToDate, University of Alabama Birmingham Research FoundationNo other potential conflicts of interest were reported.